AUTHORS
Niels van de Donk, MD, PhD, Ajay K Nooka, MD, MPH2, Roberto Mina, MD3, Luciano J. Costa, MD, PhD4, Rahul Banerjee, MD5, Maria-Victoria Mateos Jr, MD, PhD6, Nizar Bahlis, MD7, Vania Hungria, MD, PhD8, Salomon Manier, MD, PhD9, Wenming Chen10, Aurore Perrot Sr, MD11, Edvan de Queiroz Crusoé, MD, PhD, MSc12, Surbhi Sidana, MD13, Murali Janakiram, MBBS14, Maximilian Merz, MD15, Muhamed Baljevic, Director, Multiple Myeloma Program, Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP)16, Gurbakhash Kaur, MD17, Cyrille Touzeau Sr, MD, PhD18, Guldane Cengiz Seval, MD, PhD19, Eduardo Rego20, Swarup Kumar, MBBS21, Rafael Fonseca, MD22, Weili Sun, MD, PhD23, Priya Shah, MBBS24, Robin Carson, MD25, Dai Wang26, Hui Li27, Tzu Min Yeh28, Maria Rubin29, Lamar Hunt30
AFFILIATIONS
1 Department of Hematology, Amsterdam University Medical Center, Cancer Center Amsterdam Vrije Universiteit Amsterdam, Amsterdam, Netherlands
2 Emory University, Winship Cancer Institute, Atlanta, Georgia, United States
3 Division of Hematology, Department of Molecular Biotechnology and Health Sciences, AOU Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy, Emory University, Winship Cancer Institute, Atlanta, Georgia, United States
4 Division of Hematology and Oncology, The University of Alabama at Birmingham, Birmingham, Alabama, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
6 Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer (Universidad de Salamanca-Consejo Superior de Investigaciones Científicas), CIBERONC, Salamanca, Spain
7 Arnie Charbonneau Cancer Institue, University of Calgary, Calgary, Alberta, Canada
8 Clinica São Germano, São Paulo, Brazil
9 Maladies du Sang, Centre Hospitalo-Universitaire, Lille, France
10 Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
11 Universite de Toulouse, Centre Hospitalier Universitaire, Service d'Hematologie IUCT Oncopole CRCT, Toulouse, France
12 D'Or Institute for Research and Education, Department of Internal Medicine, Federal University of Bahia, Salvador, Brazil
13 Stanford University School of Medicine, Palo Alto, California, United States
14 Judy & Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Durate, California, United States
15 Department of Medicine, Multiple Myeloma and Transplant and Cellular Therapy Services, Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, United States
17 Icahn School of Meidicne at Mount Sinai, New York, New York, United States
18 Department of Hematology, University Hospital of Nantes, Nantes, France
19 Ankara University Faculty of Medicine, Department of Hematology and Oncology, Ankara University, Ankara, Turkey
20 Center for Cell Therapy, Foundation for Research Support of the State of São Paulo, São Paulo, Brazil, Laboratory of Medical Research in Pathogenesis and Target Therapy in Onco-Immuno-Hematology, Department of Interal Medicine, Division of Hematology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil
21 Division of Hematology and Oncology, Neag Comprehensive Cancer Center, University of Connecticut Health, Farmington, Connecticut, United States
22 Division of Hematology and Oncoloy, Mayo Clinic, Scottsdale, Arizona, United States
23 Johnson & Johnson, Los Angeles, California, United States
24 Johnson & Johnson, High Wycombe, United Kingdom
25 Johnson & Johnson, Spring House, Pennsylvania, United States
26 Johnson & Johnson, Raritan, New Jersey, United States
27 Johnson & Johnson, Shanghai, China
28 Johnson & Johnson, Raritan, New Jersey, United States
29 Johnson & Johnson, Raritan, New Jersey, United States
30 Johnson & Johnson, Raritan, New Jersey, United States
ABSTRACT
Introduction: Teclistamab (Tec) is the only BCMA×CD3 BsAb approved for the treatment of RRMM as early as second line. In the phase 3 MajesTEC-3 and MajesTEC-9 trials, Tec with daratumumab (Tec-Dara) and Tec monotherapy, respectively, significantly improved PFS (Tec-Dara: HR, 0.17; Tec: HR, 0.29; P<0.0001) and OS (0.46 [P<0.0001]; 0.60 [P=0.002]), versus standard-of-care (SOC) in patients (pts) with RRMM and 1-3 prior lines of therapy (pLOTs). Early infections were observed across treatment groups, including SOC, consistent with RRMM-associated immune dysfunction and higher disease burden. Treatment-related hypogammaglobulinemia due to BCMA-associated B-cell depletion further underscores the importance of early, guideline-based infection management in these pts. Phase 3 protocols recommended, but did not require, IgRT use, resulting in variable use across sites consistent with local standards. Guidance evolved across studies with protocol amendments, leading to progressively earlier and more consistent use over time.
Given the evolution of IgRT use over time, we sought to model the impact of continuous IgRT use on the risk of grade ≥3 infection in pts receiving Tec-based regimens by applying an MSM to data from MajesTEC-3/-9
Methods: Tec was administered at 1.5 mg/kg QW in cycle (C)1-2 (preceded by 2 step-up doses); 3 mg/kg Q2W in C3-6; and 3 mg/kg Q4W in C7+. MajesTEC-3 pts also received Dara. In both trials, infection prophylaxis, including antimicrobial agents, was administered according to institutional guidelines per protocol. Study protocols recommended IgRT prior to the first treatment dose to maintain Ig ≥400 mg/dL; recommendations were proactively reinforced with protocol amendments in both studies as experience with Tec evolved.
As IgRT was not randomly assigned, standard comparisons are susceptible to confounding. We therefore applied an MSM to Tec-based arms from MajesTEC-3/-9 to estimate the causal effect of two IgRT strategies on grade ≥3 infection risk: continuous IgRT (defined as ≥1 dose of IgRT within every 28-day period starting from just before C1D1) versus observed IgRT use (defined as each pt’s actual on-trial IgRT use, which could include no use, a single dose, intermittent or continuous dosing). Baseline covariates (age, BMI, sex, race, pLOT, ISS stage, and MM subtype) and time-varying confounders, including functional IgG status (M-protein corrected for IgG subtype of MM) at baseline or time of measurement (≤400 vs >400 mg/dL) and cumulative number of low-grade infections, were adjusted for using stabilized inverse probability weights. The primary outcome was time to first treatment-emergent grade ≥3 infection; pts were followed from the start of treatment until last dose +30 days, start of subsequent therapy, end of study, or clinical cut-off, whichever occurred first. Pts without a grade ≥3 infection by the end of follow-up were censored. Bootstrapped 95% CIs were computed for risk difference (RD) and risk ratio (RR) at 1 year of follow-up.
Results: A total of 283 and 291 pts received ≥1 dose of Tec-Dara or Tec, respectively, yielding a pooled Tec population of 574 pts. Median follow-up was 34.5 months in MajesTEC-3 and 17.3 months in MajesTEC-9.
In MajesTEC-3 and MajesTEC-9, 1.4% and 6.9% of pts, respectively, received IgRT prior to first treatment dose reflecting infrequent early IgRT use relative to contemporary guideline recommendations.
The estimated cumulative risk of first grade ≥3 infection at 1 year was lower under continuous versus observed IgRT use across populations: 20.6% versus 39.4% for Tec-Dara (RD, -18.8%; 95% CI -26.9%, -10.0%; RR, 0.52; 95% CI 0.33, 0.74), 21.7% versus 38.0% for Tec (RD, -16.3%; 95% CI -21.7%, -9.6%; RR, 0.57; 95% CI 0.44, 0.75), and 21.0% versus 38.3% for the pooled Tec population (RD, -17.3%; 95% CI -21.9%, -12.4%; RR, 0.55; 95% CI 0.44, 0.67). Results were consistent across sensitivity analyses. Additional analyses, such as recurrent-event analysis of overall cumulative infection risk, will be presented.
Conclusion: In this MSM analysis of MajesTEC-3/-9, a hypothetical continuous IgRT strategy was associated with an estimated ≥45% reduction in the risk of experiencing a first grade ≥3 infection by 1-year compared with observed IgRT use. While infection risk in RRMM remains multifactorial, these results suggest that earlier and more consistent implementation of guideline-based IgRT may help to mitigate infection risk in pts receiving Tec-based therapy.
DISCLOSURES
Niels van de Donk, MD, PhD: Janssen Pharmaceuticals - Honoraria; Servier - Honoraria; Kite Pharma - Honoraria; Bayer - Honoraria; Takeda - Honoraria; Janssen Pharmaceuticals - Honoraria; Novartis - Honoraria; Roche - Honoraria; Sanofi - Honoraria; Celgene - Honoraria; Roche - Honoraria; Merck - Honoraria; Galapagos - Honoraria; Bayer - Honoraria; Bristol Myers Squibb - Honoraria; BMS - Honoraria; Sanofi - Honoraria; Novartis - Honoraria; Amgen - Honoraria; Merck - Honoraria; Takeda - Honoraria; Adaptive - Honoraria; Celgene - Honoraria; Kite Pharma - Honoraria; Pfizer - Honoraria; Amgen - Honoraria; AbbVie - Honoraria; Servier - Honoraria; Pfizer - Honoraria; Galapagos - Honoraria; Adaptive Biotechnologies - Honoraria; AbbVie - Honoraria; Cellectis - Research Funding; Novartis - Research Funding; Janssen Pharmaceuticals - Research Funding; Amgen - Research Funding; CellCentric - Research Funding; AMGEN - Research Funding; Novartis - Research Funding; Celgene - Research Funding; BMS - Research Funding; BMS - Research Funding; CellCentric - Research Funding; Amgen - Research Funding; Celgene - Research Funding; Janssen - Research Funding; Cellectis - Research Funding; NOVARTIS - Research Funding; CELLECTIS - Research Funding; Novartis - Research Funding; Janssen Pharmaceuticals - Research Funding; Bristol Myers Squibb - Research Funding; Pfizer - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Janssen Pharmaceuticals - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Bayer - Consultancy (Includes expert testimony); Galapagos - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); AMGEN - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Kite Pharma - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Galapagos - Consultancy (Includes expert testimony); BAYER - Consultancy (Includes expert testimony); Adaptive - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); NOVARTIS - Consultancy (Includes expert testimony); TAKEDA - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Bayer - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Janssen Pharmaceuticals - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); ROCHE - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Kite Pharma - Consultancy (Includes expert testimony)